Back to Search Start Over

Generation of human ILC3 from allogeneic and autologous CD34 + hematopoietic progenitors toward adoptive transfer.

Authors :
Van der Meer JMR
Bulder I
Kuijk C
Kleijer M
Verheij MW
Omar SZ
Haverkate NJE
Dolstra H
Blom B
Hazenberg MD
Voermans C
Source :
Cytotherapy [Cytotherapy] 2024 Feb; Vol. 26 (2), pp. 136-144. Date of Electronic Publication: 2023 Dec 25.
Publication Year :
2024

Abstract

Type 3 innate lymphoid cells (ILC3) are important in tissue homeostasis. In the gut, ILC3 repair damaged epithelium and suppress inflammation. In allogeneic hematopoietic cell transplantation (HCT), ILC3 protect against graft-versus-host disease (GvHD), most likely by restoring tissue damage and preventing inflammation. We hypothesize that supplementing HCT grafts with interleukin-22 (IL-22)-producing ILC3 may prevent acute GvHD. We therefore explored ex vivo generation of human IL-22-producing ILC3 from hematopoietic stem and progenitor cells (HSPC) obtained from adult, neonatal and fetal sources. We established a stroma-free system culturing human cord blood-derived CD34 <superscript>+</superscript> HSPC with successive cytokine mixes for 5 weeks. We analyzed the presence of phenotypically defined ILC, their viability, proliferation and IL-22 production (after stimulation) by flow cytometry and enzyme-linked immunosorbent assay (ELISA). We found that the addition of recombinant human IL-15 and the enhancer of zeste homolog 1/2 inhibitor UNC1999 promoted ILC3 generation. Similar results were demonstrated when UNC1999 was added to CD34 <superscript>+</superscript> HSPC derived from healthy adult granulocyte colony-stimulating factor mobilized peripheral blood and bone marrow, but not fetal liver. UNC1999 did not negatively impact IL-22 production in any of the HSPC sources. Finally, we observed that autologous HSPC mobilized from the blood of adults with hematological malignancies also developed into ILC3, albeit with a significantly lower capacity. Together, we developed a stroma-free protocol to generate large quantities of IL-22-producing ILC3 from healthy adult human HSPC that can be applied for adoptive transfer to prevent GvHD after allogeneic HCT.<br />Competing Interests: Declaration of Competing Interest The authors declare no competing interests.<br /> (Copyright © 2023 International Society for Cell & Gene Therapy. Published by Elsevier Inc. All rights reserved.)

Details

Language :
English
ISSN :
1477-2566
Volume :
26
Issue :
2
Database :
MEDLINE
Journal :
Cytotherapy
Publication Type :
Academic Journal
Accession number :
38149947
Full Text :
https://doi.org/10.1016/j.jcyt.2023.11.011